Neopterin, tryptophan and kynurenine as biomarkers in glioblastoma.

Authors

Petr Krupa, Lenka Kujovska Krcmova, Marketa Krupova, Katerina Matousová, Simona Paulikova, Petra Kasparova, Bohuslav Melichar, Tomas Cesak

Published in

Scientific reports. Jul 15, 2026. Epub Jul 15, 2026.

Abstract

Glioblastoma (GBM) is a highly aggressive brain tumor with limited prognostic markers to predict patient outcomes reliably. This study investigates the perioperative levels of tryptophan, kynurenine, and neopterin in patients with GBM to assess their potential as biomarkers for prognosis. Twenty-four patients with supratentorial GBM and 24 age- and gender-matched healthy controls were included. Blood and urine samples were collected at four time points: preoperatively, three days postoperatively, prior to adjuvant therapy, and post-adjuvant therapy. Analytical measurements of tryptophan, kynurenine, and neopterin levels were conducted using liquid chromatography-tandem mass spectrometry, and statistical analyses were performed to determine their correlation with survival outcomes. The analysis revealed significant perioperative fluctuations in neopterin, kynurenine and tryptophan levels in GBM patients. Moreover, a trend (p = 0.08) of an association between preoperatively obtained blood level of kynurenine and survival probability was observed supporting further validation of kynurenine-pathway biomarkers in larger, molecularly annotated cohorts.

PMID:
42449127
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.